Holen Sie sich die Stockscreener-App
6.58
0.61%
0.04
Handel nachbörslich:
6.58
Schlusskurs vom Vortag:
$6.54
Offen:
$6.52
24-Stunden-Volumen:
124.13K
Relative Volume:
0.57
Marktkapitalisierung:
$354.55M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-32.77M
KGV:
-9.4229
EPS:
-0.6983
Netto-Cashflow:
$-29.56M
1W Leistung:
+6.30%
1M Leistung:
-9.62%
6M Leistung:
-6.67%
1J Leistung:
+87.46%
1-Tages-Spanne:
$6.4301
$6.64
1-Wochen-Bereich:
$5.71
$6.64
52-Wochen-Spanne:
$3.2805
$10.42
Diamedica Therapeutics Inc Stock (DMAC) Company Profile
Firmenname
Diamedica Therapeutics Inc
Sektor
Branche
Telefon
(763) 496-5454
Adresse
301 CARLSON PARKWAY, MINNEAPOLIS, MN
Compare DMAC vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DMAC
Diamedica Therapeutics Inc
|
6.58 | 352.39M | 0 | -32.77M | -29.56M | -0.6983 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Diamedica Therapeutics Inc Stock (DMAC) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-14 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2025-10-30 | Eingeleitet | TD Cowen | Buy |
| 2024-10-07 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-04-24 | Fortgesetzt | Craig Hallum | Buy |
| 2023-06-22 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2021-04-09 | Eingeleitet | Oppenheimer | Outperform |
| 2021-02-17 | Eingeleitet | ROTH Capital | Buy |
| 2020-10-30 | Eingeleitet | Guggenheim | Buy |
| 2020-07-08 | Eingeleitet | Maxim Group | Buy |
| 2019-04-30 | Eingeleitet | Dougherty & Company | Buy |
| 2019-03-05 | Eingeleitet | Lake Street | Buy |
Alle ansehen
Diamedica Therapeutics Inc Aktie (DMAC) Neueste Nachrichten
EBITDA per share of DiaMedica Therapeutics Inc. – NASDAQ:DMAC - TradingView — Track All Markets
Is DiaMedica Therapeutics Inc a cyclical or defensive stock2026 Market Sentiment & Precise Swing Trade Alerts - baoquankhu1.vn
Returns Recap: How does DiaMedica Therapeutics Inc compare to its peers2026 Geopolitical Influence & Technical Entry and Exit Tips - baoquankhu1.vn
RedChip's April 16 Virtual Investor Conference to Feature Companies Advancing Clinical Pipelines and Scalable Healthcare Platforms - marketscreener.com
Q1 EPS Estimate for DiaMedica Therapeutics Raised by Analyst - MarketBeat
What is HC Wainwright’s Forecast for DMAC FY2029 Earnings? - Defense World
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Diamedica Therapeutics (DMAC), Elevance Health (ELV) and Oric Pharmaceuticals (ORIC) - The Globe and Mail
HC Wainwright Issues Pessimistic Estimate for DMAC Earnings - MarketBeat
Top Wall Street forecasters revamp DiaMedica Therapeutics expectations ahead of Q4 earnings - MSN
[ARS] DiaMedica Therapeutics Inc. SEC Filing - Stock Titan
Equity plan expansion at DiaMedica (NASDAQ: DMAC) adds 3.5M shares - Stock Titan
H.C. Wainwright reiterates DiaMedica stock rating on trial progress By Investing.com - Investing.com India
H.C. Wainwright reiterates DiaMedica stock rating on trial progress - Investing.com
DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Q4 2025 Earnings Call Transcript - Insider Monkey
DiaMedica Therapeutics Furnishes 2025 Financial Results and Business Update - The Globe and Mail
DMAC Should I Buy - Intellectia AI
DiaMedica Therapeutics Inc (DMAC) Q4 2025 Earnings Call Highlights: Strong Cash Position and ... By GuruFocus - Investing.com Canada
DiaMedica Therapeutics Inc.Common Stock - FinancialContent
DiaMedica Therapeutics Reports 2025 Financial Results - National Today
DiaMedica reiterates plan for ReMEDy2 interim analysis in 2H 2026 as stroke trial approaches 70% of 200 patients - MSN
DiaMedica Therapeutics Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
DiaMedica Therapeutics Q4 Earnings Call Highlights - MarketBeat
Earnings call transcript: DiaMedica Therapeutics Q4 2025 shows liquidity boost By Investing.com - Investing.com South Africa
Earnings call transcript: DiaMedica Therapeutics Q4 2025 shows liquidity boost - Investing.com
DiaMedica Therapeutics Reports Full Year 2025 Financial Results and Provides Business Highlights - BioSpace
Loss Report: Is DiaMedica Therapeutics Inc a cyclical or defensive stockTrade Analysis Report & AI Optimized Trading Strategy Guides - baoquankhu1.vn
DiaMedica Therapeutics (DMAC) Strengthens Financial Position and Advances Clinical Programs - GuruFocus
Rising R&D widens loss as DiaMedica (NASDAQ: DMAC) funds DM199 - Stock Titan
DiaMedica Therapeutics (NASDAQ:DMAC) Issues Quarterly Earnings Results, Meets Expectations - MarketBeat
DiaMedica Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
DM199 pipeline: DiaMedica Therapeutics (NASDAQ: DMAC) targets stroke and preeclampsia - Stock Titan
Top Wall Street Forecasters Revamp DiaMedica Therapeutics Expectations Ahead Of Q4 Earnings - Benzinga
DiaMedica Therapeutics, Inc. (NASDAQ:DMAC) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
DiaMedica Therapeutics Inc expected to post a loss of 18 cents a shareEarnings Preview - TradingView
Price Action: Can DiaMedica Therapeutics Inc keep up with sector leadersRate Cut & Weekly Watchlist of Top Performers - baoquankhu1.vn
Can DiaMedica Therapeutics Inc keep up with sector leadersRate Cut & Weekly Watchlist of Top Performers - baoquankhu1.vn
DiaMedica Therapeutics (DMAC) Projected to Post Earnings on Tuesday - Defense World
DiaMedica Therapeutics to Report Fourth Quarter 2025 Financial Results and Provide a Business Update March 31, 2026 - weeklyvoice.com
DiaMedica schedules March 31 call for 2025 results, business update - Stock Titan
DiaMedica Therapeutics appoints Julie Krop as Chief Medical Officer - MSN
Market Review: How does DiaMedica Therapeutics Inc compare to its peers2026 Technical Patterns & Expert Verified Movement Alerts - baoquankhu1.vn
Cooperman Leon G Raises Position in DiaMedica Therapeutics, Inc. $DMAC - MarketBeat
Does DiaMedica Therapeutics (DMAC) Have the Potential to Rally 114.06% as Wall Street Analysts Expect? - MSN
DiaMedica receives Health Canada clearance for preeclampsia study - Investing.com Nigeria
Analysts Offer Insights on Healthcare Companies: Savara (SVRA), Codexis (CDXS) and Diamedica Therapeutics (DMAC) - The Globe and Mail
Finanzdaten der Diamedica Therapeutics Inc-Aktie (DMAC)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.69%
0.25%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):